The selection committee of the BaseLaunch Accelerator has revealed the ten projects entering Phase I. During the next four to six months, the project teams will work with experts and advisers from various fields to develop their business ideas. Up to 10,000 Swiss francs will be available for each project.
Managed and operated by BaselArea.swiss, BaseLaunch Accelerator has entered the second cycle of the program with ten projects in phase 1. They range from therapeutics and diagnostics to digital healthcare and more. Some projects are still in the early stages development, others are currently run by established startups.
Neil Goldsmith, Director Strategy BaseLaunch says: “A strong life sciences hub like Basel needs to maintain a dynamic startup scene with excellent quality. With BaseLaunch, we can add that value and provide a much sought-after boost for new ventures and corporations alike.”
The selection committee chose the most promising projects to enter Phase I of the Accelerator. These include
Avicenna Oncology, BS: Avicenna Oncology GmbH is a biotechnology startup, created in 2014 in Basel, Switzerland. Their lead program consists of ImmunoPayloads (ImPs), First In Class immuno-oncology therapeutics with a unique and innovating mode of action.
SiBreax, ZH: SiBreaX develops stimulus responsive silicate-based nano-/microparticles for targeted drug/compound delivery and degradable, injectable nanocomposite hydrogels for biomedical and topical applications. Leveraging its platform technology of nano-/microparticles and hydrogels, SiBreaX partners in development as well as develops own drugs and medical hydrogels.
Cureab GmbH, BS: Cureab develops antibodies for cancer therapy focussing on lung, liver and colorectal cancer.
CMET Pharmaceuticals: CMET Pharmaceuticals aims to develop novel therapies for the treatment of metastatic cancers, tailored to target circulating tumour cell clusters
Pattern Biosciences, BS: Next generation programmable therapies powered by Synthetic Biology.
Epibloc: Epibloc applies a proprietary immunoprofiling platform to identify peptides that bind to specific autoantibodies involved in autoimmune diseases. The peptides are then used to develop companion diagnostics and precision drugs to eliminate only the disease causing autoantibodies.
SynEndoS Therapeutics: Developing a new medicine to treat anxiety and stress related disorders by modulating the activity of cannabinoid molecules already present in the human body.
Biotech in stealth mode: Discovery and development of new eye therapeutics for diseases with unmet medical need
Biotech in stealth mode: Developing a novel digital therapeutic for the treatment of migraine
Biotech in stealth mode: Developing novel cell engineering-based treatments.
The ten selected startups have four to six months to develop their business ideas. In this process, they are supported by the BaseLaunch team as well as by a number of experienced entrepreneurs and consultants. In this first phase, up to 10,000 Swiss francs will be available for each of the projects. The selection committee will then select about three of the Phase I projects to progress to Phase II. This phase lasts at least for 12 months, with each project receiving funding of up to 250,000 Swiss francs.
(Press release/ran)
Please login or sign up to comment.
Commenting guidelines